Express Scripts Holding Company Raises EPS Forecast
Image source: Express Scripts.
Express Scripts Holding Company (NASDAQ: ESRX) reported second-quarter results on July 25. Even as it remains locked in a heated lawsuit with its biggest customer, the pharmacy benefits manager once again boosted its full-year earnings outlook.
The raw numbers
|
Q2 2016 |
Q2 2015 |
Growth (YOY) |
|
|---|---|---|---|
|
Revenue |
$25.22 billion |
$25.45 billion |
(1%) |
|
Net Income |
$720.7 million |
$600.1 million |
20% |
|
Earnings Per Share |
$1.13 |
$0.88 |
28% |
Data source: Express Scripts Q2 2016 earnings press release. YOY = year over year.
What happened with Express Scripts this quarter?
- Adjusted prescriptions claims fell 2% year over year to 315.3 million.
- EBITDA (earnings before interest, taxes, depreciation, and amortization) per adjusted claim increased 2% to $5.70.
- Net income -- adjusted to exclude integration costs and other non-recurring items -- grew 2% to$998.7 million. And adjusted earnings per share, which were boosted by stock buybacks, rose 9% to$1.57.
Anthem update
Regarding its ongoing contract dispute with health issuer Anthem (NYSE: ANTM), Chairman and CEO Tim Wentworth had this to say during a conference call with analysts:
Wentworth noted the dispute with Anthem might not be resolved in the near future:
As Express Scripts' largest customer, Anthem, accounts for about 14% of the pharmacy benefits manager's revenue in 2014. In addition, many investors fear the situation with Anthem could impact Express Scripts' contract negotiations with its other customers.
Seemingly to quell these concerns, Express Scripts said it expects its retention rate for the 2016 selling season to be in the range of 96% to 98%, excluding some business that's already slated to roll off 2017. That's up from the company's prior projections of 95% to 98%.
Looking forward
Management expects second-quarter adjusted earnings per share to be between $1.72 and $1.76, which would represent growth of 19% to 21% from the prior-year period.
Express Scripts also narrowed its full-year adjusted EPS forecast to a range of $6.33 to $6.43, up from previous estimates of $6.31 to $6.43 given in April, $6.10 to $6.28 issued in February, and initial guidance of $6.08 to $6.28 provided back in December. This new EPS outlook signifies an increase of 14% to 16% compared to 2015.
"As the healthcare industry changes, a primary need of payers and patients remains the same: access to affordable medicine," said Wentworth in a press release."An increase in our expected 2017 retention rate to a range of 96% to 98% is a direct result of our unique business model of client alignment, the industry's most focused and innovative solutions, and a compassionate culture of caring employees."
A secret billion-dollar stock opportunity The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early, in-the-know investors! To be one of them, just click here.
Joe Tenebruso has no position in any stocks mentioned. The Motley Fool owns shares of and recommends Express Scripts. The Motley Fool recommends Anthem. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.